Skip to main content

Topic

Biosimilars

856 published works

  1. Big Molecule Watch

    FDA Approves Lannett, Lanexa Biologics, and Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar

    By Zachariah Holmes

    On May 4, 2026, the FDA approved Lannett Company, Inc. (“Lannett”), Lanexa Biologics LLC (“Lanexa”), and Sunshine Lake Pharma’s LANGLARA (insulin glargine-aldy) as an interchangeable biosimilar to Sanofi’s LANTUS (insulin…

  2. Big Molecule Watch

    FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars

    By Allegra Padula

    The U.S. Food and Drug Administration (“FDA”) recently released its congressional justification for the 2027 Fiscal Year budget.  Overall, the FDA proposed a total budget of $7.2 billion, an overall…

  3. Big Molecule Watch

    Biocon Launches Denosumab Biosimilars

    By Timothy Beavers

    On April 7, 2026, Biocon Limited announced that it had launched BOSAYA (denosumab-kyqq) and AUKELSO (denosumab-kyqq) in the United States.  Both products are RANK ligand inhibitors used to treat conditions…

  4. Big Molecule Watch

    Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar

    By Allegra Padula

    On March 30, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced that the U.S. Food and Drug Administration (“FDA”) has approved its denosumab biosimilar, PONLIMSI (denosumab-adet).  PONLIMSI has been approved for…

  5. Big Molecule Watch

    Amgen and Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation

    By Riley Wyberg

    On March 31, 2026, the District Court for the District of New Jersey entered a Consent Order and Judgment in the BPCIA litigation Amgen brought against Henlius and Organon concerning…

  6. Big Molecule Watch

    Bio-Thera and Intas Expand Golimumab Biosimilar Partnership to India

    By Yoko Bian

    On March 23, 2026, Bio-Thera Solutions announced an expansion of its existing partnership with Intas Pharmaceuticals for BAT2506, its golimumab biosimilar referencing Janssen’s SIMPONI®. The updated agreement grants Intas exclusive…

  7. Big Molecule Watch

    Celltrion Announces AVTOZMA (tocilizumab-anoh) Now Available in U.S.

    By Kristin Beale

    On March 16, 2026, Celltrion, Inc. announced the U.S. commercial launch of AVTOZMA® (tocilizumab-anoh) SC, a subcutaneous formulation of its tocilizumab biosimilar referencing Roche’s ACTEMRA. Celltrion had previously launched its…

  8. Big Molecule Watch

    Samsung Bioepis and Sandoz Expand Potential Portfolios Through New Research and Development Collaborations

    By Timothy Beavers

    On March 18, 2026, Sandoz announced a new license, development, and commercialization partnership agreement with Samsung Bioepis Co., Ltd.  Under this agreement, the companies will collaborate on the development and…

  9. Big Molecule Watch

    Update: Janssen Files BPCIA Complaint Against Bio-Thera and Accord Related to Golimumab Biosimilar

    By Natasha Daughtrey|Christopher Cassella

    As we reported last week, Janssen Biotech, Inc. and Janssen Sciences Ireland UC (collectively, “Janssen”) filed under seal a BPCIA complaint in the U.S. District Court for the District of…

  10. Big Molecule Watch

    FDA Issues Draft Guidance Further Streamlining Biosimilar Development

    By Sarah Adam

    On March 9, 2026, the U.S. Food and Drug Administration (FDA) issued new draft guidance aimed at further streamlining the development of biosimilar and interchangeable biosimilar products by reducing certain…